[HTML][HTML] Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours
Background & Aims Immune-related liver injury (irLI) is commonly observed in patients with
cancer treated with immune checkpoint inhibitors (ICIs). We aimed to compare the
incidence, clinical characteristics, and outcomes of irLI between patients receiving ICIs for
hepatocellular carcinoma (HCC) vs. other solid tumours. Methods Two separate cohorts
were included: 375 patients with advanced/unresectable HCC, Child-Pugh A class treated
with first-line atezolizumab+ bevacizumab from the AB-real study, and a non-HCC cohort …
cancer treated with immune checkpoint inhibitors (ICIs). We aimed to compare the
incidence, clinical characteristics, and outcomes of irLI between patients receiving ICIs for
hepatocellular carcinoma (HCC) vs. other solid tumours. Methods Two separate cohorts
were included: 375 patients with advanced/unresectable HCC, Child-Pugh A class treated
with first-line atezolizumab+ bevacizumab from the AB-real study, and a non-HCC cohort …
111P Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma compared to patients with advanced solid tumours
Background Immune-related liver injury (irLI) is commonly observed in patients with cancer
treated with immune checkpoint inhibitors (ICIs). In this comparative study, we aimed to
compare incidence, clinical characteristics and outcomes of irLI between patients receiving
ICIs for HCC versus other solid tumour indications. Methods Two separate cohorts were
included: 375 patients with advanced/unresectable HCC, Child-Pugh A class treated with
first-line Atezolizumab+ Bevacizumab from AB-real study and a non-HCC cohort, including …
treated with immune checkpoint inhibitors (ICIs). In this comparative study, we aimed to
compare incidence, clinical characteristics and outcomes of irLI between patients receiving
ICIs for HCC versus other solid tumour indications. Methods Two separate cohorts were
included: 375 patients with advanced/unresectable HCC, Child-Pugh A class treated with
first-line Atezolizumab+ Bevacizumab from AB-real study and a non-HCC cohort, including …
以上显示的是最相近的搜索结果。 查看全部搜索结果